Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07606235

Transcutaneous Superior Laryngeal Nerve Stimulation to Upregulate Swallowing Frequency and Urge to Swallow in Patients Living With ALS

Prospective, single-arm pilot study evaluating transcutaneous electrical nerve stimulation of the superior laryngeal nerve (TENS-SLN) in individuals with ALS.

Up to 5 participants with confirmed ALS and bulbar involvement will be enrolled.

Primary outcomes: swallowing frequency and perceived urge to swallow. Participants complete a baseline visit, followed by two supervised treatment sessions within one week, and a final post-treatment evaluation.

Optional visits (up to 2) may be used to individualize stimulation parameters prior to treatment.

Swallowing function will be assessed using physiological monitoring, fiberoptic endoscopy, and videofluoroscopic swallow study (VFSS).

TENS-SLN is a non-invasive neuromodulation approach targeting sensory pathways to facilitate swallowing without inducing muscle contraction.

This pilot study is designed to assess feasibility, safety, and preliminary effect sizes to inform future randomized trials, and is not powered to determine efficacy.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

This prospective, single-arm interventional pilot study will evaluate the acute effects of transcutaneous electrical nerve stimulation of the superior laryngeal nerve (TENS-SLN) on swallowing function in individuals with amyotrophic lateral sclerosis (ALS). Up to five participants with confirmed ALS and bulbar involvement will be enrolled. The primary outcomes are swallowing frequency and perceived urge to swallow.

Participants will complete a baseline assessment followed by two supervised TENS-SLN treatment sessions conducted within a one-week period. Up to two additional visits may be performed prior to treatment to optimize individualized stimulation parameters. Treatment sessions may take place in the clinic or the participant's home under clinician supervision. A final in-clinic evaluation will be completed at the end of the study period. Swallowing function will be assessed using physiological monitoring, fiberoptic endoscopy, and videofluoroscopic swallow study (VFSS) at baseline and post-intervention.

TENS-SLN is a non-invasive neuromodulation approach that delivers low-intensity electrical stimulation via surface electrodes placed over the anatomically accessible superior laryngeal nerve in the anterior neck. The intervention is designed to enhance sensory input to swallowing-related neural circuits and facilitate swallow initiation without directly eliciting muscle contraction.

This pilot study is not powered to determine efficacy but is intended to assess feasibility, safety, and preliminary effect sizes to inform the design of future randomized controlled trials. All study procedures are performed for research purposes and are not part of standard clinical care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed diagnosis of ALS (El-Escorial Criteria)
  • ALS FRS Bulbar Subscore of ≤ 10 and ≥ 3.
  • Functional Oral Intake scale score ≥ 2

Exclusion criteria

  • A diagnosis of significant cognitive impairment or frontotemporal dementia per the treating neurologist or neuropsychologist,
  • Current nasogastric tube placement
  • Current head and neck carcinoma
  • Pacemaker or implanted defibrillator or history of diagnosed arrhythmia, bradycardia, or repeated attacks of hypotension,
  • Implanted vagal nerve stimulator
  • Current pregnancy
  • History of epilepsy
  • Infected, broken or inflamed skin on the neck, or impaired sensation at the site of sEMG or TENS placement
  • Living greater than 50 miles from the NSU clinic round trip
  • Any clinical reason that this stimulation may not be a suitable treatment according to the principal investigator.

Treatment and study plan

Transcutaneous Superior Laryngeal Nerve Stimulation to Upregulate Swallowing Frequency and Urge to Swallow

Other

Transcutaneous Superior Laryngeal Nerve Stimulation to Upregulate Swallowing Frequency and Urge to Swallow in ALS

Primary outcomes

  1. Swallowing Frequency

    Time frame: From enrollment to the end of the 7-day follow-up period

    The count of swallows per unit time with predefined epochs

  2. Urge-to-swallow

    Time frame: Measured from enrollment to the end of the 7 day follow up period

    patient reported urge to swallow during rest and stimulation periods on a modified Borg scale, 0 (very easy) to 10 (very difficult to elicit a swallow)

Secondary outcomes

  1. Body weight gain/loss

    Time frame: At Day 1 and at Day 7

    The total body weight (lbs)

  2. Maximum Expiratory Pressure

    Time frame: From enrollment to the end of the 7-day follow up period

    Maximum expiratory pressure achieved during forceful exhalation

  3. Lingual pressure assessment

    Time frame: At baseline (Day 1) pre-procedural, on Day 1 post-procedure, and on Day 7

    Maximum lingual pressure and saliva swallowing pressures will be obtained using the IOPI oral performance in 3 instances.

  4. Peak cough flow

    Time frame: One at enrollment and one at the end of the 7- day folow-up period

    Maximum expiratory flow achieved during the expulsive phase of the cough (PCF, L/min)

  5. Videofluoroscopic Swallowing Evaluation

    Time frame: At baseline and at the end of the 7-day follow-up period

    Yale residue Scale to assess post-swallow residue in the pharynx following swallow trials. (5 point ordinal scale; graded 1 being none -5 being severe) Dynamic Imaging Grade of Swallowing Toxicity for FEES safety, efficiency, and total scores. (each subscore is graded on scale from 0-4; 0 being no impairment, being profound/life-threatening impairment)

  6. Fiberoptic Endoscopic Evaluation of Swallowing (FEES)

    Time frame: At baseline and again at the end of the 7 day follow up period

    New Zealand Secretion Scale to assess oropharyngeal secretions and clearance response on a 7-point ordinal scale. (Maximum 7- Minimum 0) Laryngeal Kinematics: presence of vocal fold adduction and abduction

  7. Body Weight (BMI)

    Time frame: Day 1 - Day 7

    Total BMI measured at Baseline (day 1) and at the end of th study (Day 7)

Study contacts

Contact information is provided by the study sponsor or research team.

Racquel Garcia, SLPD, CCC-SLP

CONTACT

[email protected]

(954) 262-1271

Sponsors and collaborators

Lead sponsor

Nova Southeastern University

Other

Collaborators

  • Curators of the University of Missouri

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 26, 2026
Registry last updated
May 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.